A large body of experimental data has demonstrated the central role of T cells in acquired resistance to the dimorphic fungus Blastomyces dermatitidis. We examined the human T-cell response to WI-1, a 120-kDa B.
Blastomycosis, one of the principal endemic systemic mycoses, results from an infection with the thermal dimorphic fungus Blastomyces dermatitidis. Humans and lower animals, such as dogs, are primarily infected by inhaling aerosolized conidia from soil, in which the organism dwells as a saprophyte (19) . At body temperature, the conidia are converted to the parasitic or invasive yeast forms that cause disease. The acute primary pulmonary infection can be asymptomatic or can produce an influenza or atypical pneumonia syndrome (47) . Although acute blastomycotic pneumonia may resolve spontaneously, progressive forms of disease involving the lungs, the extrapulmonary organs (usually the skin, bones, joints, or prostate gland), or both develop in many patients.
The central role of cell-mediated immunity, especially thymus-derived lymphocytes (T cells), in the immunologic control of granulomatous fungal disease is highlighted by the emergence of disseminated histoplasmosis (53) , coccidioidomycosis (8) and, most recently, blastomycosis (43) as opportunistic infections in AIDS patients. A large body of experimental data has demonstrated that specific cellular immunity is a principal component of acquired resistance to B. dermatitidis (9, 17, 48, 52) . In a murine model of blastomycosis, protective immunity can be adoptively transferred to naive mice with T cells (9) . In humans, nearly all individuals infected with B. dermatitidis develop specific cellular * Corresponding author. immunity, as determined by in vitro lymphocyte proliferation in response to yeast cell wall determinants in the crude antigen preparation, Blastomyces alkali-and water-soluble antigen (B-ASWS) (4, 5, 30, 32) . The response correlates with enhanced in vitro phagocytosis and inhibition of the growth of B. dermatitidis by peripheral blood monocytederived (7) and alveolar (6) macrophages, and the supernatant from antigen-stimulated T cells endows macrophages of nonimmune donors with comparable microbicidal function (6) . Murine studies have extended these data and examined the influence of gamma interferon on macrophage killing of B. dermatitidis. Peritoneal macrophages treated with a dose of 10,000 U/ml show significantly enhanced killing of yeast cells (10) . The results of these studies have led to the conclusion that activated macrophages are the principal effector cells of resistance; they acquire their microbicidal activity after stimulation with lymphokines released from antigen-specific T cells. However, the phenotype and function of the cells and the ligands recognized have not been fully defined.
The development of B-ASWS by Cox and Larsh (15) has permitted experimental (18, 23) , clinical (4, 5) , and epidemiological (30, 32) studies of cellular immune responses in blastomycosis. The antigen is extracted from yeast cell walls with 1 N NaOH, which cleaves a-1,3-glucan linkages in the outermost layer and yields a complex mixture of lipid, polysaccharide, and protein with a molecular weight of 30,000 to 50 ,000 (16) . Preparative polyacrylamide gel electrophoresis and isoelectric focusing have shown that B-ASWS possibly contains three or four fractions (33) . One fraction confers the high sensitivity and specificity, whereas the others appear to account for cross-reactivity with heterologous fungi, particularly Histoplasma capsulatum. Indeed, lymphocytes from histoplasmin-reactive subjects proliferate in response to B-ASWS (13) , albeit to a significantly lower extent than lymphocytes from blastomycosis patients (5) . Despite the considerable value of B-ASWS, the technique that isolates the antigen may thwart further attempts to purify and characterize immunodominant T-cell epitopes of B. dermatitidis. Alkali extraction denatures (15) and markedly fragments (34) the protein components.
In view of this difficulty in further defining determinants of B-ASWS and, in turn, T cells directed against them, we studied whether Blastomyces-reactive lymphocytes from infected persons were directed against a recently described 120-kDa surface protein antigen on B. dennatitidis yeast cells, designated WI-1. The results from the study demonstrate that WI-1 is a specific target of the T-cell response in human blastomycosis, that WI-1 and B-ASWS share immunodominant epitopes, and that the manner of display of the epitopes in conjunction with major histocompatibility (MHC) class II may influence the profile of the immune response.
MATERIALS AND METHODS Lymphocytes. Peripheral blood lymphocytes (PBL) from patients and control subjects were obtained by Ficoll-Hypaque sedimentation of anticoagulated whole blood as previously described (51) . Some cells were cryopreserved in 10% dimethyl sulfoxide by controlled-rate freezing and stored in liquid nitrogen for later use (12) .
Antigens. The isolation and partial purification and characterization of WI-1 have been described (31) . In that study, the antigen was partially purified by electroelution for the principal purpose of radiolabeling with 1"I to detect antibody in infected patients. In the present study, WI-1 from B. dennatitidis yeast cells (ATCC 60636) was purified to homogeneity by high-performance liquid chromatography (HPLC) (unpublished data). HPLC-purified WI-1 is a glycoprotein that contains only minimal polysaccharide (4.1% estimated carbohydrate content), as assessed by the phenol-sulfuric acid method (dextran standard) (20) .
Other antigens used included B-ASWS, prepared as described previously (15) Cloning of T cells. Single-cell-derived clones were generated at a limiting dilution (36) . In brief, 6-day cultures of antigen-stimulated lymphocytes were expanded for 48 h with 25 to 50 U of recombinant interleukin-2 (IL-2) (Cetus Corp., Emeryville, Calif.) per ml. Activated lymphocytes were then cultured in 0.25-ml round-bottom microtiter plate wells at an average quantity of 0.8 cell per well with 0.2 ml of HS-RPMI containing 2 x 104 gamma-irradiated (3,000 cGy) autologous PBL, 104 gamma-irradiated (8,000 cGy) autologous EpsteinBarr virus B-lymphoblastoid (EBV-LCL) cells, IL-2 at 20 U/ml, a 5% final dilution of a supernatant from a 3-day culture of PBL with 1,000 U of IL-2 per ml, and an appropriate concentration of stimulating antigen. Preliminary experiments showed that 20 p,g of B-ASWS per ml was optimal for cloning Blastomyces-reactive T cells and that 5 ,ug of histoplasmin per ml was optimal for cloning Histoplasma-reactive T cells. Cultures were incubated at 37°C in a 5% CO2 humidified incubator. Cells were isolated from wells showing growth after 3 to 4 weeks. They were screened for proliferative and cytotoxic responses (described below) to autologous EBV-LCL antigen-presenting cells in the presence and absence of fungal antigen, and antigen-reactive clones were expanded, each clone on a separate 96-well microtiter plate. Initial clonal expansion and restimulation every 10 to 14 days were performed with microtiter plate wells as in the original cloning. Some clones were cryopreserved at -135°C, thawed, and restimulated in the same manner.
Proliferation assays of clones. Minor modifications were made in antigen-induced proliferation assays to study the antigen responsiveness of clones or antigen-primed PBL in secondary assays. In brief, 105 responding cells were cultured in triplicate in 0.25-ml flat-bottom microtiter plate wells (Costar) with HS-RPMI containing 5 x 104 gammairradiated autologous EBV-LCL cells (8, Table 2) .
Cloning of antigen-specific T cells. We cloned T cells from patient 5 that were specific for Blastomyces antigenic determinants. The cloning strategy took advantage of the observations that WI-1 contained only (or mostly) Blastomycesunique determinants and that WI-1 and B-ASWS shared immunologically important determinants. Thus, fresh PBL were stimulated in vitro for 6 days to enrich WI-1 antigenspecific T cells, and the cells were expanded with IL-2 (25 U/ml) for 48 h and cloned in the presence of B-ASWS. One hundred twenty-five T-cell clones were obtained from 1,800 wells plated with antigen-activated cells, a cloning efficiency of 6.9%. Of these clones, 80% responded in screening proliferation assays to Blastomyces antigens WI-1 and B-ASWS, whereas 20% responded to the antigen-presenting cells alone (autologous EBV-LCL cells) and were therefore directed against Epstein-Barr virus-encoded determinants (24) . Twelve representative clones (10 Blastomyces-reactive and 2 EBV-LCL-reactive clones) were selected for detailed study, and the remainder were cryopreserved.
We also cloned Histoplasma-reactive T cells from a histoplasmin-positive donor, individual 11 responded to either antigen after processing by nonfixed cells (Fig. 1) . In contrast, in a parallel experiment, paraformaldehyde fixation did not influence the presentation by EBV-LCL cells of mycobacterial peptide antigens to appropriately responsive -yb T-cell clones (data not shown) (21) .
Antibody blocking experiments were used to identify the MHC molecules that displayed WI-1 to the T-cell clones. The clones recognized WI-1 in association with HLA class II D loci of the MHC. The cytotoxic clones recognized epitopes together with HLA-DP, whereas the noncytotoxic clones recognize epitopes together with HLA-DR. Results for representative clones are illustrated in Fig. 2 . The lysis of targets by cytotoxic clones K -15f and K. 21b was reduced approximately 75% by an MAb directed against the CD3 polypeptide of the TCR complex, nearly abrogated by an MAb directed against a monomorphic determinant of HLA-DP, and relatively unaffected by an MAb directed against HLA-DR, HILA-DQ, or MHC class I molecules. Similar restriction patterns for these clones were demonstrated in proliferation assays (data not shown). In contrast, the proliferative response of clones K. le and K. 20f and other Blastomycesreactive clones that proliferated but did not kill was virtually eliminated by an MAb directed against HLA-DR but relatively uninfluenced by MAbs directed against other class II loci. Isotype controls IgGl and IgG2A had no influence on proliferation or cytotoxicity (data not shown).
DISCUSSION
In this report, we demonstrate that WI-1, a 120-kDa surface protein of B. dermatitidis, is a specific target of the cellular immune response in blastomycosis. Lymphocytes from recently and actively infected patients recognized and responded to the antigen in a standard in vitro proliferation assay. This finding should not be surprising, since WI-1 is an immunodominant target of antibody directed against B. dermatitidis (31), and most B-cell responses to protein antigens require antigen-specific T-cell help for antibody production (26) . In contrast to findings for blastomycosis patients, lymphocytes from histoplasmosis and other control subjects showed no response to WI-1, and T-cell clones reactive with WI-1 showed no response to heterologous fungal antigens. Although there is extensive sharing of cell wall determinants in B. dermatitidis and other dimorphic fungi (45) negligible titers of antibody to WI-1 in histoplasmosis, coccidioidomycosis, and sporotrichosis patients with high titers to the respective fungi and suggests a lack of cross-reactive B-cell epitopes on WI-1 (31).
It appears that WI-1 shares important T-cell epitopes with B-ASWS, which has been the standard T-cell antigen used for cellular studies of blastomycosis. We showed that enriching patient lymphocytes for WI-1 (or B-ASWS)-reactive T cells produced an equivalent response to either WI-1 or B-ASWS in a secondary proliferation assay. The T-cell cloning strategy that we used was based on this observation.
We hypothesized that lymphocytes enriched for WI-i-reactive T cells would be directed against cell wall determinants uniquely present in B. dermatitidis and that cloning of the cells in the presence of B-ASWS would expand T cells that recognize the dominant epitopes of B-ASWS also expressed on the WI-1 molecule. The antigen reactivity and specificity of the clones that we derived support this hypothesis. They all responded to both B. dennatitidis antigens but not other antigens. All of the clones studied in depth are ao T cells that express the CD4 antigen, an accessory molecule of the TCR complex that enables interactions with class II MHC molecules. We cannot exclude the possibility that some of the other clones that were not phenotyped and studied in detail express a different phenotype. Alternatively, the initial enrichment of antigen-specific T cells and cloning conditions may have been biased toward the growth and selection of CD4+ T cells. Another study has shown that cloning in the presence of IL-4, rather than IL-2, leads to the proliferative expansion of CD8+ T cells (42) . However, the processing of a soluble fungal antigen through the exogenous pathway and the subsequent association of the antigen with class II MHC molecules would likely dictate that a major component of the response would be mediated by class II-restricted CD4+ T cells (38) .
Further phenotyping of the clones suggested the preferential usage of a particular V gene element of the TCR, Vf8, in the immune response to WI- (37) .
A subset of the CD4+ T-cell clones that we studied demonstrated strong, specific cytotoxic responses against WI-1 antigen-labeled targets. To our knowledge, antigenspecific T cells with direct cytolytic effects have not been described previously for the immune response to B. dermatitidis or other dimorphic fungi. However, recent studies with mice and humans infected with Mycobacterium spp. and other intracellular organisms have identified cytolytic T cells (1, 28, 29, 39, 44, 46) . In murine models of listeriosis and tuberculosis, CD8+ cytolytic T cells confer protection to naive mice in adoptive transfer experiments (29, 39) , suggesting that these cells play a key role in acquired resistance. The precise role of CD4+ cytolytic T cells in the immune response has not been clarified, but recent studies of human tuberculosis have proposed that such cells may be involved in regulating T-and B-cell responses by directly lysing the MHC class II-bearing cells presenting the 65-kDa heat shock protein antigen of mycobacteria (41) . These investigators suggested that this type of immunoregulation may explain why tuberculoid leprosy patients are good cytotoxic T-cell responders and have low specific antibody titers, whereas the opposite is true for lepromatous leprosy patients. A similar striking discordance between antibody production and the proliferative T-cell response has been documented in cases of progressive coccidioidomycosis (14) , but the involvement of cytolytic T cells has not been explored. The finding of cytolytic T cells in human blastomycosis raises several questions that require future study. (i) Do these effector cells kill or inhibit the growth of conidia or yeasts or produce tissue injury and immunopathology? (ii) Is cytotoxicity mediated directly by effector-target binding and the release of lytic granules (25) or indirectly by secretion of lymphokines, such as tumor necrosis factor I8 (22) ? (iii) Are cytolytic T cells a consistent feature of the immune response in blastomycosis, or might the unusual HLA restriction pattern of the potent killers K. 15f and K. 21b here indicate that this feature is unique to a subset of patients with a particular HLA background?
We examined the requirements for antigen processing and presentation of WI-1 antigen to T-cell clones. Paraformaldehyde fixation of EBV-LCL cells eliminated the metabolic activity of the cells and abrogated the presentation of WI-1. These observations are consistent with the view that WI-1 is a large globular protein that requires uptake and denaturation within antigen-presenting cells and subsequent charging of peptide epitopes with MHC molecules for surface membrane display. We were surprised that fixation also impaired the presentation of B-ASWS to the clones, since that antigen is somewhat denatured and certain other peptide antigens can bind directly to cell surface MHC and be presented to T cells without processing (50) . Our findings suggest, however, that the fragmented determinants in B-ASWS require additional processing for proper display of the T-cell epitopes. The small residual T-cell response to either of these antigens presented by fixed EBV-LCL cells could reflect a response to either very low molecular weight breakdown products present in limited quantities in the antigens or very minor epitopes that can be recognized on unprocessed forms of the antigens, as has been described for selected epitopes on the fibrinogen molecule (2) .
MHC class II molecules were required for the display of WI-1 and B-ASWS epitopes to the clones. Antibody blocking experiments demonstrated that most of the Blastomycesreactive clones responded to epitopes displayed by class II products of the HLA-DR gene locus. The potent cytotoxic clones, however, responded to epitopes displayed by class II products of the HLA-DP locus. It is not known whether these clones responded differently because they recognized a different antigenic epitope or because a common epitope was displayed in a different manner by an unusual restricting element. Very few soluble antigens whose presentation requires MHC products of the HLA-DP locus have been described (40) . Might the allelic expression of genes at this locus influence binding to selected epitopes and, in turn, the profile of the immune response? Using a murine model of leishmaniasis, Scott et al. (49) showed that a single HPLC fraction of soluble leishmania antigen contains a component that may activate either a Thl subset of helper T cells that confers protection to naive animals or a Th2 subset that exacerbates the disease in these animals. This observation suggests either that different epitopes alter the profile of the immune response or that common epitopes displayed differently alter this profile. This suggestion raises the question of how the HLA background and various allelic forms of class II MHC molecules may influence either the manner of binding and presentation of immunodominant epitopes of WI-1 or the composition of T cells in the host's repertoire generated during thymic selection and, in turn, the profile of the immune response to WI-1.
Clarification of the immunodominant epitopes of WI-1 recognized by the clones described here, the regulatory and effector functions of the clones themselves, and the influence of human HLA loci and alleles on the response of T cells to WI-1 will serve to advance our understanding of the pathogenesis of blastomycosis and of the cellular defense mechanisms that control this and other endemic systemic mycoses.
